WHO recommendations on shorter treatment of multidrug-resistant tuberculosis

The Lancet

Volumn 387, Issue 10037, 2016, Pages 2486-2487

  Sotgiu, Giovanni ^a   Tiberi, Simon ^b   D'Ambrosio, Lia ^c,d   Centis, Rosella ^c   Zumla, Alimuddin ^e   Migliori, Giovanni Battista ^c  

^a UNIVERSITY OF SASSARI   (Italy)

^b BARTS HEALTH NHS TRUST   (United Kingdom)

^c IRCCS   (Italy)

^d Public Health Consulting Group SAGL   (Switzerland)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; ETHAMBUTOL; ISONIAZID; KANAMYCIN; MEROPENEM; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC THERAPY; DRUG COST; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; NOTE; PRIORITY JOURNAL; TREATMENT DURATION; WORLD HEALTH ORGANIZATION; DRUG ADMINISTRATION; PRACTICE GUIDELINE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; PRACTICE GUIDELINES AS TOPIC; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH ORGANIZATION;

EID: 84975042205     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)30729-2     Document Type: Note

References (14)

1. WHO Global Tuberculosis Report 2015 who.int/tb/publications/global-report/en (accessed May 25, 2016).
2. WHO Multidrug-resistant tuberculosis (MDR-TB) www.who.int/tb/challenges/mdr/mdr-tb-factsheet.pdf 2015 (accessed May 25, 2016).
3. WHO The end TB strategy www.who.int/tb/post2015-strategy/en 2014 (accessed May 25, 2016).
4. GB Migliori, G Sotgiu, NR Gandhi Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis Eur Respir J 42 2013 169 179
5. JA Caminero, A Scardigli Classification of antituberculosis drugs: a new proposal based on the most recent evidence Eur Respir J 46 2015 887 893
6. S Ghimire, MS Bolhuis, M Sturkenboom et al. Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics Eur Respir J 2016 10.1183/13993003.00040-2016 published online March 17.
7. WHO Treatment guidelines for drug-resistant tuberculosis www.who.int/tb/MDRTBguidelines2016.pdf 2016 (accessed May 20, 2016).
8. A Piubello, SH Harouna, MB Souleymane et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses Int J Tuberc Lung Dis 18 2014 1188 1194
9. A Van Deun, AK Maug, MA Salim et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis Am J Respir Crit Care Med 182 2010 684 692
10. KJ Aung, A Van Deun, E Declercq et al. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients Int J Tuberc Lung Dis 18 2014 1180 1187
11. S Tiberi, MC Payen, G Sotgiu et al. Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB Eur Respir J 47 2016 1235 1243
12. S Tiberi, G Sotgiu, L D'Ambrosio et al. Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB Eur Respir J 2016 10.1183/13993003.00214-2016 published online April 13.
13. RS Wallis, M Maeurer, P Mwaba et al. Tuberculosis - advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers Lancet Infect Dis 16 2016 e34 e46
14. A Zumla, M Rao, RS Wallis for the Host-Directed Therapies Network consortium Host-directed therapies for infectious diseases: current status, recent progress, and future prospects Lancet Infect Dis 16 2016 e47 e63